blood-istock-507120082-blackjack3d-
blackjack3d / iStockphoto.com
23 January 2018Americas

Sanofi to buy Bioverativ for $11.6bn

Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 February 2018   Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020   Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.

More on this story

Americas
19 February 2018   Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020   Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.

More on this story

Americas
19 February 2018   Switzerland-based Roche has revealed plans to acquire a healthcare technology company for $1.9 billion.
Europe
19 April 2018   France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.
Americas
5 March 2020   Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix.